Biotech2k Profile picture
Oct 8 19 tweets 4 min read Twitter logo Read on Twitter
🧵T cell VDJ Recombination:

Here we will look more into the T cell receptor creation.
1/ The T cell will begin the arrangement of its Beta chain of the T cell receptor. This works in a competitive environment as both sets of genes from mom and dad compete to see which one is able to rearrange a successful Beta chain first.
2/ The genes for the Beta chain are located on chromosome 7. They are divided into 3 categories of the Variable genes, the Diversity genes and the Joining genes. Image
3/ There are about 60 different variable genes to choose from, usually represented as V1 to V60. There are 27 Diversity genes to choose from, represented D1 to D27. Then there are 6 different Joining genes to choose from represented as J1 to J6.
4/ The enzymes that regulate the recombination process will randomly choose 1 Variable, 1 Diversity and 1 Joining gene.
5/ There are many possible combinations of these genes. During this process all the genes between the selected segments are removed and broken down. It starts by picking a single D and J segment and putting them together and removing the DNA in between.
6/ Then it continues to take a random V gene and bind it to the already connected DJ segment removing the DNA between them. This brings together a single VD&J segment to make a Beta chain which will be transcribed. Image
7/ This leaves the T cells with just 1 choice for each of these VDJ genes. Not every gene segment has to be removed in recombination. For example, if the RAG enzymes select V20 out of 60 possible gene choices, all the genes before that are left in the DNA from V1 to V19.
8/ The same happens with the J genes. The genes after the one selected are left inside the DNA after the recombination. There are never any D segments left except the one chosen as all the rest are removed between them and the V and D segments.
9/ The first Beta chain to reach a successful arrangement and display it on the cell surface will win. The other genes for the opposite chromosome and the Delta/Gamma genes will all be inactivated.
10/ This is the process of allelic exclusion to ensure each T cell only makes 1 receptor. If the T cell fails to make a successful Beta chain for any reason with either allele, it will try to make a Gamma chain from both alleles of that gene.
11/ This acts like a rescue for the cell to try another receptor. About 95% of the T cells will have an Alpha/Beta receptor and 5% will end up with Delta/Gamma receptors.
12/ The next step will be to rearrange the alpha genes which are on chromosome 14. The alpha chain has only 2 gene categories to draw from. They are the Variable and Joining genes. There are about 70 possible genes in the Variable category to choose from, represented V1 to V70. Image
13/ There are another 61 or so genes in the Joining Category to choose from, represented J1 to J61. The alpha genes have no Diversity category. The location for the Delta genes are actually inside the Alpha genes located between the Variable and Joining genes.
12/ A successful arrangement of the alpha chain removes the Delta genes so no possible arrangement of those genes can occur. When the T cell receptor forms it will create there loops called the Complementarity Determining Regions (CDR) loops. Image
13/ The Variable gene is about 100 nucleotide long and makes up the CDR1 and CDR2 loops. The combination of the end of the V the D and the J all come together to make up the CDR3 loop. This makes CDR3 the hypervariable loop.
14/ Due to the fact that when the enzymes paste together the V, D, and J segments, some random nucleotides will be added or even removed. This creates vast diversity in this region of the TCR. Image
15/ This happens with the Beta chain in big way as it has 3 genes coming together in this CDR3 region of the receptor. The alpha chain has CDR3 region made up of the connection of the V and J region. Its not quite and hypervariable as the beta chain.
16/ The CDR1 and CDR2 mostly interact with MHC which is why they need to be consistent. The CDR3 is what recognized the antigen peptide which is why it is hypervariable. This allow for a vast repertoire of T cells to be created.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Biotech2k

Biotech2k Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @Biotech2k1

Sep 14
🧵Taking a look at $RXRX:

I have done many threads on Recursion and the potentially game changing technology behind the company. This thread will be to look at the actual company.
1/ The first thing is the pipeline. They have 3 programs that they in licensed which are all in phase 2. They have multiple programs going now from their Recursion OS. Image
2/ They have 2 major partnerships the big one is for Roche which they can do up to 40 programs with each program worth upward of $300 million in milestones. All in, I think its about $12.5 billion in biobucks. Image
Read 8 tweets
Aug 14
Taking a look at @InSilicoMeds which is a software company in the #tebhbio space. They appear to be similar to @AtomwiseInc. They are building #AI, #MachineLearning, and #DeepLearning software tools for all stages of drug discovery..
1/ They are not just developing a single platform. They have 3 platforms which are designed for different roles in drug discovery process. Image
2/ They are already using these platforms to develop a pipeline. They have a ton of programs in discovery. Image
Read 5 tweets
Aug 14
Taking a look at @AtomwiseInc which is a software company in the #tebhbio space. They appear to be similar to Schrodinger. They are building #AI, #MachineLearning, and #DeepLearning software for modeling proteins and small molecule interactions.
1/ One of the major problems with proteins in understanding how the protein and small molecule drug interact. #AtomNet is their software platform that is being developed and trained on modeling and predicting the protein and drug interaction. Image
2/ They are using their platform do focus on drug development which I love so much more than Schrodinger. They already have a pipeline of a few targets like Tyk2.
Read 4 tweets
Aug 14
A look at the #science behind $ABSI. This company is in the #techbio space. They are combining #synbio, #MachineLearning and #generativeAI to take on a new approach to antibody discovery.
1/ They start with #synbio using their #SoluPro platform which takes Ecoli and uses it to create humanized proteins. This can be used to produce both antigen proteins and antibody proteins. Image
2/ From my understanding, they are using the SoluPro to produce both antibody and proteins with tags on them. They then run a massive "speed dating" like assay where the proteins and antibodies are put together to see how they respond. Maybe @SeanRMcClain can correct me on this.
Read 8 tweets
Aug 14
A look at the #science behind $SDGR. This company is in the #techbio space. They are the company building the #AI and #MachineLearning applications for drug discovery.
1/ Their platform is for developing the #software that models physics based chemistry. They license or partner their software to other companies for drug discovery. Image
2/ This technically makes $SDGR a software company. A company like @Relay_Tx uses some of the software they license from Schrodinger to drive their #Dynamo platform. This makes Schrodinger a key player in the #techbio space with software development.
Read 7 tweets
Aug 14
A look at the #science behind $RLAY. This company is in the #techbio space. They are using technologies to model proteins in motion. They take images of proteins across their entire of work cycle over time. This allows them to model how they move in real time.
1/ They will use technologies like CryoEM and Xray Crystallography to capture images of the protein in motion across time. All those images go into their simulations. Image
2/ The data from the imaging goes into their #Dynamo platform which uses #AI and #MachineLearning to model the proteins in motion. They can predict efficacy and potential side effects.
Read 8 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(